A new perspective on macrophage-targeted drug research: the potential of KDELR2 in bladder cancer immunotherapy
2024

KDELR2's Role in Bladder Cancer Immunotherapy

Sample size: 40 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zhao Zhiyi, Jia Hongling, Sun Zhou, Li Yumeng, Liu Lingyun

Primary Institution: The First Hospital of Jilin University

Hypothesis

KDELR2 is a promising therapeutic target in bladder cancer immunotherapy.

Conclusion

KDELR2 promotes bladder cancer cell proliferation, invasion, and migration, indicating its potential as a target for immunotherapy.

Supporting Evidence

  • KDELR2 expression correlates with poor survival in bladder cancer patients.
  • High KDELR2 levels are associated with increased macrophage infiltration.
  • KDELR2 enhances bladder cancer cell proliferation and migration.
  • Single-cell RNA sequencing identified distinct tumor cell subpopulations.
  • Prognostic analysis revealed KDELR2 as a key factor in patient outcomes.

Takeaway

Researchers found that a protein called KDELR2 helps bladder cancer cells grow and spread, which could be important for new treatments.

Methodology

The study used single-cell RNA sequencing and clinical data to construct an RNA transcriptome map of bladder cancer.

Potential Biases

Potential bias due to the focus on a specific cancer type and small sample size.

Limitations

The study's sample size was small, and it primarily focused on urothelial carcinoma, limiting generalizability.

Participant Demographics

The study included bladder cancer patients with diverse demographic backgrounds.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1485109

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication